Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients

被引：0
|
作者：
Takayuki Takimoto
Tasuku Nakabori
Akio Osa
Satomu Morita
Haruko Terada
Susumu Oseto
Takashi Iwazawa
Kinya Abe
机构：
[1] Toyonaka Municipal Hospital,Department of Internal Medicine
[2] Toyonaka Municipal Hospital,Department of Surgery
来源：
International Journal of Clinical Oncology | 2012年 / 17卷
关键词：
Non-small-cell lung cancer (NSCLC); Chronic renal failure; Docetaxel; Tubular nephrotoxicity; β; -Microglobulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Renal dysfunction is a characteristic of many patients with cancer; however, a standard therapy has not been established for stage III or IV non-small-cell lung cancer (NSCLC) complicated with chronic renal failure. Docetaxel has a proven significant activity against NSCLC. This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients. Docetaxel is, thus, a therapeutic option in that patient population. Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. Little is known about tubular nephrotoxicity induced by docetaxel; however, oncologists should be aware of its possibility.
引用
收藏
页码：395 / 398
页数：3
相关论文
共 50 条
  • [1] Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients
    Takimoto, Takayuki
    Nakabori, Tasuku
    Osa, Akio
    Morita, Satomu
    Terada, Haruko
    Oseto, Susumu
    Iwazawa, Takashi
    Abe, Kinya
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (04) : 395 - 398
  • [2] Integration of docetaxel in the management of non-small-cell lung cancer
    Belani, CP
    LUNG CANCER, 2004, 46 : S1 - S2
  • [3] Development of docetaxel in advanced non-small-cell lung cancer
    Belani, CP
    Eckardt, J
    LUNG CANCER, 2004, 46 : S3 - S11
  • [4] Docetaxel in the treatment of advanced non-small-cell lung cancer
    Saloustros, Emmanouel
    Georgoulias, Vassilis
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (08) : 1207 - 1222
  • [5] Docetaxel for previously treated non-small-cell lung cancer
    Fossella, FV
    ONCOLOGY-NEW YORK, 2002, 16 (06): : 45 - 51
  • [6] Docetaxel plus cisplatin in non-small-cell lung cancer
    Chandra Belani
    Sakkaraiappan Ramalingam
    Vassilis Georgoulias
    George Simon
    Drugs & Therapy Perspectives, 2004, 20 (3) : 7 - 9
  • [7] Gefitinib or docetaxel in advanced non-small-cell lung cancer
    Cullen, Michael
    Thatcher, Nicholas
    LANCET, 2008, 372 (9652): : 1785 - 1786
  • [8] Weekly chemotherapy of cisplatin and docetaxel for elderly patients with non-small-cell lung cancer
    Ohe, Y
    Niho, S
    Minami, H
    Saijo, N
    Watanabe, K
    Yokoyama, A
    Nishiwaki, Y
    LUNG CANCER, 2004, 45 : S76 - S77
  • [9] Docetaxel Versus Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer
    Karampeazis, Athanasios
    Georgoulias, Vassilis
    CLINICAL LUNG CANCER, 2012, 13 (05) : 397 - 397
  • [10] Docetaxel as monotherapy in the treatment of advanced non-small-cell lung cancer in elderly patients
    Malani, Ashok K.
    Abou-Jawde, Rony M.
    Singh, Jaswinder
    Taylor, Sarah A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) : 1143 - 1144
12345